Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
This report studies the eosinophilic esophagitis drug market.
Scope of the Report:
The classification of eosinophilic esophagitis drug includes budesonide, fluticasone and other types, and the proportion of budesonide in 2017 is about 52%.
North America is the largest consumption region of eosinophilic esophagitis drug, with a sales market share nearly 32% in 2017. Europe is the second largest consumption region of eosinophilic esophagitis drug, enjoying Sales market share nearly 29% in 2017.
Market competition is intense. AstraZeneca, GSK, Bayer are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Eosinophilic Esophagitis Drug is expected to grow at a CAGR of roughly 6.2% over the next five years, will reach 150 million US$ in 2024, from 100 million US$ in 2019, according to a new WMR study.
This report focuses on the Eosinophilic Esophagitis Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Dr. Falk Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eosinophilic Esophagitis Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Eosinophilic Esophagitis Drug, with price, sales, revenue and global market share of Eosinophilic Esophagitis Drug in 2017 and 2018.
Chapter 3, the Eosinophilic Esophagitis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eosinophilic Esophagitis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Eosinophilic Esophagitis Drug market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Eosinophilic Esophagitis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.